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ABSTRACT
DESIGNING A MICROBIAL PROLYL PEPTIDASE DELIVERY SYSTEM FOR THE
TREATMENT OF CELIAC DISEASE
Matthew J. Shurtleff

Celiac disease is an autoimmune enteropathy resulting from the ingestion of
gluten and gluten-like proteins from wheat, barley and rye in afflicted individuals.
Indigestible gluten-derived peptides rich in proline residues are known to be responsible
for eliciting the inappropriate immune response characteristic of the disease. In this
investigation, surface level expression of prolyl peptidase activity by genetically
engineered probiotic lactobacilli was postulated to be a possible treatment for this
disease. Plasmid-based reporter vectors were constructed utilizing a novel, homologybased cloning technique to assess the expression and localization signals from the S-layer
protein gene of Lactobacillus acidophilus. These plasmids were mutated during
construction due to toxicity associated with the cloned cassettes. The toxicity of the Slayer secretion and/or anchoring domains in E. coli was confirmed by cloning the fused
components into an inducible expression system. When the prolyl peptidase, Xaa-Pro,
from L. reuteri was incorporated into the S-layer expression cassette, the full-length
protein was efficiently expressed but was not active, likely due to protein aggregation and
inclusion body formation. Future research directions are discussed and a modified
experimental design strategy is presented. This work provides a foundation for continued
investigation into the feasibility of utilizing genetically engineered lactobacilli as a
potential treatment strategy for celiac disease.
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1.0 Background

1.1 Celiac Disease Background

1.1.1 General information: Definition, Symptomology, Gross Pathology, Prevalence and
Diagnosis
Celiac disease (coeliac disease, celiac sprue, CD) is an auto-immune enteropathy
resulting from sensitivity to epitopes contained within gluten, the dominant protein
portion of many common grains including wheat, barley and rye. Exposure to these
proteins leads to inflammation and widespread atrophy of intestinal epithelia in
individuals with CD. Since these grains are ubiquitous in the average western diet, celiac
disease greatly detracts from the quality of life enjoyed by those not suffering from CD.
Symptoms of CD are generally similar to other chronic gastrointestinal disorders
such as Crohn’s disease and ulcerative colitis, thus it is commonly misdiagnosed in both
children and adults (Picarelli et .al., 2000; Corazza et al., 1996) . Common
gastrointestinal symptoms include abdominal pain and cramping, flatulence, diarrhea,
constipation and bloating. Chronic inflammation of cells lining the small intestine results
in shortening and eventual complete destruction of villi. This leads to common
extraintestinal manifestions of the disease, such as anemia, as well as other complications
due to chronic malabsorption. CD primarily affects the proximal portion of the small
intestine (the duodenum), but in some cases can extend into the ileum (Ruben et al.,
1962). A subset of CD patients will develop a skin rash (dermatitis herpetiformis) in
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response to the ingestion of gluten that will resolve after administration of dapsone (the
mechanism for this is not well understood). However, it should be noted that even if the
only symptom of CD is dermatitis herpetiformis, the intestinal pathology is still
manifested and these individuals remain at high risk for a number of celiac-associated
conditions (Collin et al., 1996). The onset of CD symptoms varies within the population
ranging from infancy to late adulthood. Diagnosis in young children is often very difficult
due to the non-specific nature of the symptoms in this age group (failure to thrive,
anorexia, pallor, musle atrophy), which may lead to misdiagnosis (Ciclitira, 2005).
Approximately 50% of diagnosed CD sufferers will not be diagnosed until adulthood,
although the proportion of these individuals in which the onset of symptoms does not
occur until adulthood as opposed to those whose symptoms were previously sub-clinical
is not known. The prevalence of CD is approximately 1:100 among the Caucasian
population, making it the most commonly diagnosed chronic gastrointestinal disorder
(Ciclitira et al., 2005). Surveys of CD prevalence in other racial groups are sparse and
poorly documented, likely because the Caucasian population is the most dependent on
gluten containing grains as a primary nutritional source.
In cases in which CD is expected the patient will often be screened for the
presence of auto-reactive antibodies (anti-endomysial and anti-tissue transglutaminase).
Also, genetic screening can be useful as there is a strong genetic association with CD in
the class II major histocompatibility complex (MHC-class II) HLA-DQ locus, with ~98%
of CD cases having either the DQ2 alleles (~90%) or the DQ-8 alleles (~8%) (Sollid &
Thorsby, 1993). Although both screening methods are useful in either eliminating CD as
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a possibility or narrowing down the focus of the physician, ultimately CD diagnosis must
be confirmed by intestinal biopsy.

1.1.2

Molecular pathology: The paradox
A feature of CD molecular pathogenesis that makes the disease relatively unusual

among autoimmune disorders is that the immune response, though directed at host
tissues, is actually initiated and propagated by foreign antigens derived from the partial
digestion of α-gliadin, a protein within gluten. Only recently, after the discovery of the
epitope structures recognized by auto-reactive antibodies and the subsequent elucidation
of the immunodominant gliadin-derived peptides, has a model for the initiation and
propagation of the humoral autoimmune response emerged (Figure 1-1). In order to
understand how this paradox of a foreign antigen capable of eliciting an autoimmune
response can be resolved, some consideration must first lent to major players involved in
the complex molecular pathology of this hereditary autoimmune disorder.

3
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1.1.3 Gluten and related proteins: the source of toxicity in CD
Gluten is the dominant proteinaceous portion of wheat. Closely related protein
elements are present in barley and rye grains that are also capable of eliciting the immune
response characteristic of celiac disease. For simplicity, only gluten will be discussed
here, as the overall mechanism of pathogenesis is the same between grains with only the
names differing. Gluten can be split into two general types of proteins, the glutenins (low
molecular weight proteins) and the gliadins (high molecular weight proteins, denoted αγ). While both glutenins and gliadins contain epitope structures capable of initiating an
immune response, the dominant peptides responsible for eliciting immune response
(immunodominant) are derived from α-gliadin (Shan et al., 2002).
Two short peptide epitope structures, PFPQPLPY and PQPQLPYPQ have been
identified as the primary epitopes in CD pathogenesis. The particular importance of these
two specific epitopes is evidenced by the observation that gluten specific T-cells from
nearly all CD patients respond to one or both of these peptides (Arentz-Hansen et al.,
2000). Furthermore, when these two peptides are administered to individuals that have
been on a strict gluten exclusion diet, T-cells responding to these two peptides are the
first to be detected in the peripheral blood stream (Anderson et al., 2000). Seminal work
by Lu Shan of the Khosla research group proposed that a single 33 amino acid peptide
might be the primary factor initiating an autoimmune response. This peptide, along with
another 18 amino acid peptide, have been designated as the immunodominant CD
peptides. Challenge of gut-derived T-cell lines from nearly all CD patients tested with
this 33-mer resulted in induction of these cells, giving support for the hypothesis that this
5

toxic peptide is the immunodominant peptide in the majority of CD patients. This peptide
also contains 6 partially overlapping epitope structures and is highly degradation resistant
due to the large number of proline residues (Shan et al., 2002).
Proline is unique among amino acids in that it has its side chain wrapped around
and bonded to the nitrogen atom involved in peptide bonding. This unusual bonding
scheme results in tight kinks being formed in the primary structure of peptides containing
proline. If there are a high number of proline residues the peptide will twist back upon
itself, creating a proteolysis resistant structure that cannot be degraded by common
digestive enzymes in the human gastrointestinal tract. The 33-mer peptide has a half-life
of at least 20 hours when subjected to brush border membrane digestive enzymes, with
the relatively poorly expressed peptidases dipeptidyl carboxypeptidase I and dipeptidyl
peptidase IV (DPPIV) identified as the rate limiting factors in breakdown of this
troublesome peptide (Shan et al., 2002, Hausch et al., 2002). The facts that this peptide
contains immunoreactive epitope structures and a high proline content conferring
digestive resistance are each contributing factors to toxicity. However, this only suggests
that an immune response would be targeted to gliadin, resulting in the generation of antigliadin antibodies. The question that remains is: How can this foreign peptide result in an
autoimmune response targeted against a structurally distinct and ubiquitously expressed
host enzyme (tissue transglutaminase)? An answer to this question can only be arrived at
after a thorough discussion of how CD is fundamentally a genetically-based disorder.
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1.1.4 CD as an inheritable autoimmune disease
Clear evidence of CD as an inheritable disorder has been evidenced by sibling and
twin studies. The most recent large-scale population study showed a high concordance
rate (70-75%) of CD between monozygotic twins (Greco, 2002). As previously
mentioned, a strong genetic association exists between CD and the HLA-DQ genetic
locus with the vast majority of CD sufferers possessing the HLA-DQ2 (~90%) or HLADQ8 (~8%) genotype. The HLA-DQ locus encodes MHC class II proteins responsible for
presentation of foreign proteins or peptides. When a foreign protein is encountered, it is
endocytosed by an antigen presenting cell (APC), degraded and processed in the late
endosome and loaded into the HLA-DQ heterodimer. Once loaded, the HLA-DQ+peptide
complex is delivered to the plasma membrane of the APC where it can be recognized by
the corresponding helper T-cell. Once the helper T-cell recognizes the specific antigen to
which it is programmed to respond, the cell will be activated and begin producing and
secreting cytokines. In CD, a TH1 response is mounted involving the release of IFN-γ,
resulting in inflammation and activation of the innate immune response and eventually
culminating in cellular destruction. As will be discussed later, a TH2 response also plays
an important role in CD pathology by activating B-cells to produce anti-gliadin and antitissue transglutaminase antibodies.
More than a simple genetic correlation, the HLA-DQ2 association appears to have
a functional role in CD. This version of the MHC-class II proteins has a strong
predilection for negatively charged molecules. However, immunodominant peptides do
not have an overall negative charge. How can sense be made of this apparent
7

incompatibility? To address this question a discussion of the functional role of the CD
autoantigen, tissue transglutaminase is warranted.

1.1.5 The autoantigen: tissue transglutaminase
In 1997 the autoantigen for CD was identified as tissue transglutaminase (tTG)
(Dietrich et al., 1997). Tissue transglutaminase is a ubiquitously expressed enzyme whose
primary functional role appears to be the cross-linking of fibronectin proteins during clot
formation. Under the slightly acidic conditions present in the small intestine however,
the enzymatic activity of tTG switches from cross-linking of glutamine to lysine residues
(transamidation) to deamidation (Fleckenstein et al., 2002). Deamidation of glutamine
residues results in the conversion of glutamine to glutamic acid, a negatively charged
amino acid. tTG has an extremely high affinity for the CD associated immunogenic
peptides which is strong enough to displace the enzymes primary substrate fibronectin
(Xia et al., 2005). Interestingly, it has been found that partial deamidation of glutamine
residues present in immunogenic peptides is required to initiate an immune response
whereas no deamidation or complete deamidation of the same peptides did not result in
the activation of gut derived T-cells in patients with CD (Molberg et al., 1998). This
further underlines the essential role of this host protein in the pathogenesis of CD.
Furthermore, the very close association between immunogenic peptides and tTG is also
the foundation for the current model describing how these foreign peptides can result in
an autoimmune response directed against the CD autoantigen, tTG.
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1.1.6 A case of molecular mistaken identify: A model for CD autoimmunity
The immune system contains three primary types of APCs; dendritic cells,
macrophages and B-cells. The first two cell types are the basis of the adaptive immune
response, constantly sampling the environment and presenting a wide range of potential
antigens on their surfaces to be recognized by helper T-cells. Once the helper T-cell
recognizes an antigen presented by either a macrophage or dendritic cell, a TH1 response
will be generated. In a TH1 response, the helper T-cell will begin secreting cytokines
(IFNγ among others) that promote inflammation and lead to the recruitment of other cells
involved in the immune response. Also during this response, matrix metalloproteinases
are activated leading to widespread tissue damage. It is likely that the TH1 response is
greatly amplified in CD due to the extremely high affinity of the deaminated
immunodominant peptides for the HLA-DQ2 proteins. This affinity is so strong that,
immediately following the initial influx of gliadin into the intestinal sub-mucosa, these
peptides are able to displace those antigens that are already being presented by APCs in
the lamina propria (Xia et al., 2005).
Helper T-cells that recognize antigens presented by B-cells are responsible for
mounting the TH2 response. A TH2 response leads to the activation of B-cells resulting
in the production of antibodies. B-cells are unique among antigen presenting cells in that
they can only present the specific antigen for which they are programmed to recognize.
This occurs through the binding of the antigen to surface immunoglobulin, this complex
is then endocytosed, processed in much the same was as other APCs and presented on its
surface for identification by helper T cells. This leads to activation of helper T-cells
leading to the TH2 response, resulting in the release of cytokines that signal B-cells to
9

begin producing antibodies. While there are likely to be many auto-reactive B-cells
circulating (left over from the early maturation of the immune system) these will
generally not result in auto-antibody production, because there is no corresponding helper
T-cell to signal antibody production. These auto-reactive “rogue” B-cells along with the
tight interaction between tTG and the gliadin-derivded immunodominant peptides (ID)
form the crux of the current model for the molecular pathogenesis of CD and the
production of anti-tTG antibodies.
B-cells with anti-tTG surface immunoglobulin bind to tTG interacting with ID
peptides, the tTG-ID complex is then endocytosed, processed and the antigens are
presented on the cell surface. If the processed antigen is derived from tTG, there will be
no corresponding helper T-cell dependent activation and no antibody will be produced.
However, if the presented antigens are derived from the tTG bound ID then ID specific
helper T-cells will signal the antigen presenting B-cell to produce the antibodies it is
programmed to release, anti-tTG. Again the extremely high affinity of deaminated ID
peptides for the HLA-DQ2 proteins comes into focus and plays an essential role in this
model for auto-antibody production. The affinity of ID for these proteins is so high that
they can displace other peptides that are already bound in the late endosome, thus
essentially ensuring that the deaminated peptides, rather than a fragment from tTG will be
the presented antigen (Xia et al., 2005). The exact role of anti-tTG in the intestinal
pathology of CD remains unclear and controversial. It is likely that the inflammatory
response generated from TH1 activation is the primary contributor to tissue damage and
symptomology, with the production of anti-tTG antibodies playing a lesser role in
intestinal pathology.
10

1.1.7 The role of the innate immune system and intestinal permeability in CD
The innate immune response had previously been thought to play an insignificant
role in CD pathogenesis. Recent evidence however, contradicts this viewpoint and
suggests that components of the innate immune response are necessary for the initial
influx of gliadin peptides into the intestinal sub-mucosa.
Zonulin is a protein that is commonly released in response to bacterial infection
that results in the phosporylation of proteins that maintain tight junction integrity, thus
leading to increased intestinal permeability. Gliadin exposure to normal and CD intestinal
mucosa also activates the zonulin signaling pathway (Drago et al., 2006). Recent work
has further clarified the upstream events leading to zonulin release. In this model, gliadin
peptides bind to the CXCR3 chemokine receptor in mucosal cells leading to recruitment
of the MyD88 adaptor protein which then signals the release of zonulin leading to
increased intestinal permeability (Lammers et al., 2008). This role of the innate immune
response in promoting the invasion of gliadin across the intestinal barrier and into the
lamina propryia where it can interact with members of the adaptive immune system
appears to be an essential initial step in the pathogenesis of CD. Furthermore, it has been
postulated that MyD88 dependent zonulin release may be an important contributor to a
number of other autoimmune diseases, some of which show comorbidity with CD (Watts
et al., 2005; Thomas et al., 2006).
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1.1.8 Current and possible future treatments to manage CD
The only current treatment strategy available to manage CD is the gluten-free
diet. Unfortunately, it is extremely difficult to avoid gluten entirely in a modern western
diet that is strongly founded on grains. Individuals with CD can rarely eat out at
restaurants as many common cooking components contain enough gluten to trigger an
immune response. In many cases only very small, accidental exposures can be enough to
lead to a full-scale immune response and the resulting symptoms. Furthermore, there is a
very high degree of non-compliance among CD patients on the gluten-free diet as many
individuals find the gluten-free foods unsavory, or are unaware of the presence of gluten
in their food. Indeed, gluten can be found in unexpected sources such as vitamins and soy
sauce. While the symptoms of CD may be tolerable or even sub-clinical in some
individuals, the associated conditions and long-term effects of unmanaged CD can be
severe or even fatal. These include; skin disorders, ulcerative colitis, lymphocytic colitis,
liver disease, thyroid disease, anemia, diabetes, bone metabolism, malignancy and even
neurological and psychological disturbances (Ciclitira et al., 2005). Management of
celiac disease through the gluten free diet is critical to limiting and preventing
complications, especially life threatening complications such as gastrointestinal
lymphoma and carcinoma (Corrao et al., 2001).
Recently a new treatment strategy based upon the possibility of enzyme therapy
using prolyl endopeptidases derived from bacteria or fungi has been proposed (Shan et al.
2004, Stepniak et al. 2006). These enzymes break down the immunodominant peptides
by hydrolyzing proline-Xaa bonds. Unfortunately, these enzymes would have to be
delivered as purified enzyme, since none of the organisms from which these enzymes
12

have been isolated can colonize the small intestine. As the human digestive tract is in fact
a biological system, the protein expression profile is an amalgam of both human digestive
enzymes as well as the multitude of microbial digestive enzymes produced by the
bacteria that inhabit the intestines. Armed with this knowledge, a continued exploration
into the prospects for a potential microbial-based treatment is justified.

1.2 Probiotic bacteria as enzyme delivery vehicles to manage CD

1.2.1

General probiotics background
Bacteria that stabilize the intestinal tract and promote healthy digestion are termed

probiotic. Although the term probiotic is relatively new the idea of beneficial bacteria is
as old as the study of our defenses against harmful bacteria. The term probiotic was
coined in 1965 to describe the ability of certain microorganisms to promote growth and
maturation in some animals. This definition was refined several times over the years and
a more modern definition of the term has developed to more specifically describe these
bacteria. “Probiotics is a microbial dietary adjuvant that beneficially affects the host
physiology by modulating mucosal and systemic immunity as well as improving
nutritional and microbial balance in the intestinal tract” (Naidu et al., 1999). This
definition however, may require further modification as researchers are discovering
beneficial effects of bacterial colonization throughout the body. Classically, probiotic
bacteria are primarily members of the lactic acid family of bacteria (LAB). LABs are
Gram positive, non-spore forming bacteria that produce lactic acid from the fermentation
13

of sugars. Lactobacillus is the largest genus of LABs consisting of more than 50 species
(Stiles & Holzapfel,1997; Tannock, 2004). Lactobacilli are important for the production
of foodstuffs. Most notable among these organisms are Lactobacillus delbrueckii ssp.
bulgaricus and Lactobacillus sanfranciscensis used in the commercial production of
yogurt and sourdough bread, respectively. While their primary role in food production is
the fermentation of sugars to lactic acid, non-commercially important LABs are also
responsible for producing a wide variety of compounds beneficial to humans, including
anti-microbial peptides, exopolysaccharides and other metabolites (Ross, Morgan & Hill,
2002).
An important role of probiotic bacteria in the human intestinal tract is the
regulation of intestinal homeostasis. This involves protecting the mucosal epithelium
from pathogens, delivery of regulatory signals to the immune system and neuromuscular
system, as well as inhibition of pathogenic bacteria through nutrient competition, binding
translocation and production of anti-microbial peptides (Shanahan, 2004). The genus
Lactobacillus has been shown to be effective in the treatment and prevention of
gastrointestinal disorders such as infectious diarrhea and inflammatory bowel disease
(Saavedra, 2000; Servin, 2004; Shanahan, 2004).
Probiotic bacteria must be able to bind to intestinal surfaces in order to exert their
beneficial effects. Binding to the mucosal epithelia of the intestinal tract by lactic acid
bacteria is not fully understood. Two probiotic species, Lactobacillus reuteri and
Bifidobacterium bifidum bind competitively to the same glycolipid carbohydrate moieties
in the intestinal tract that are recognized adhesion factors for enteropathogenic bacteria
(Mukai et al. 2004). Importantly, several LABs are able to survive and colonize the small
14

intestine, the primary site of gastrointestinal pathology (Marteau et al. 1997). Notably, a
strain of Lactobacillus reuteri can colonize the proximal portion of the small intestine,
the site of celiac pathology (Valeur et al., 2004)
Another potential benefit of gastrointestinal colonization by probiotic bacteria is
supplementation of enzymes in which the human intestinal tract is deficient. A wellknown example of this is the ability of lactose intolerant individuals to be able to ingest
lactose without negative symptoms after a treatment regiment of probiotic bacteria. In
this case, the individual is deficient in a functional β-galactosidase, which is provided by
the LABs that have colonized the intestines during treatment (De Vrese et al., 2001). The
lactose intolerance example makes one question what other enzymes probiotic bacteria
may express that could be beneficial to humans.

1.2.2

Prolyl peptidase activity in probiotic bacteria
Prolyl peptidase activity is conspicuously absent from the human digestive tract,

with only the poorly expressed Dipeptidyl peptidase IV able to act on proline-rich
substrates. These enzymes however can be found throughout the microbial community.
Prolyl peptidase activity can be found in abundance throughout members of the genus
Lactobacillus. Due to their inability to synthesize many amino acids, LABs are dependent
upon extracting their amino acid requirements from the environment. For this reason
LABs (especially lactobacilli) maintain an extremely complex and diverse proteolytic
system. Prolyl peptidase activity has already been characterized in several species in the
15

LAB family including, Lactobacillus helveticus, Lactobacillus sakei, Lactobacillus
reuteri and Lactococcus lactis (Degraeve et al., 2003; Sanz et al., 2001; Rollan & Font de
Valdez, 2001; Xu et al. 2002). Furthermore, LABs are capable of detoxifying glutenderived peptides during food processing (Rizzelo et al. 2007, De Angelis et al. 2006).

1.2.3 A novel treatment strategy for CD: genetically engineered probiotic bacteria
Several of the bacteria discussed in the previous section that possess prolyl
peptidases are able to colonize the intestines, including the small intestine. A bacterial
strain that can colonize the small intestine and constitutively express and secrete prolyl
peptidase enzymes at a high level would effectively supplement the area with enzymes
capable of detoxifying gluten. This approach to treatment probably will not allow
individuals with CD to eat a loaf of bread, but it may allow for tolerance of small
amounts of gluten and could therefore protect against accidental and unforeseen
exposure. Furthermore, if a probiotic bacterium such as those described in previous
sections were used, the individual would not only alleviate the CD symptoms due to
prolyl peptidase activity, but also acquire additional health benefits attributed to intestinal
colonization by probiotics. Unfortunately, no probiotic microorganism yet studied
secretes prolyl peptidase enzymes beyond the cytoplasm. However, due to the
advancements in molecular biology technology, it may now be possible to engineer
strains capable of surface expression of prolyl peptidases. This hypothetical strain would
be able to colonize the small intestine and express prolyl peptidases on the surface of the
cell, thus effectively localizing enzyme activity at the site of celiac pathology. The
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remainder of this document describes the initial research undertaken to achieve this single
goal, to provide the first non-dietary treatment option for celiac disease.
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2.0 Construction of GFP Reporter Plasmids to Assess the
Efficiency of slpA Expression and Localization Signals

2.1. Introduction
The microbial S-layer is a two-dimensional crystalline matrix that completely
covers some members of the Eubacteria, and nearly all members of the Archaea. This
specialized cellular structure is comprised of a single (with few exceptions) protein that is
able to self-assemble, in a purely thermodynamically driven process, into a highly
ordered crystalline matrix at the cell surface.
One extensively studied S-layer protein is the SlpA protein of Lactobacillus
acidophilus. The slpA gene encodes the open reading frame for the 444 amino acid SlpA
protein as well as two putative promoter sequences and a transcription termination
sequence (Boot et al., 1993; Boot et al., 1996). The slpA gene resides on a ~6 kb
chromosomal inverted repeat which contains both the slpA ORF as well as the very
closely related slpB ORF. The slpB ORF does not have a promoter sequence and thus
cannot be expressed unless a chromosomal inversion event occurs that places the slpB
ORF behind the slpA promoter, the mechanism responsible for this inversion has not yet
been identified but has been suggested to be mediated by a protein similar to the Din
invertase of E. coli (Boot et al., 1996).
The slpA gene contains two putative promoter sequences upstream of the ORF
(Figure 2-1a), however only one of these promoters (the promoter nearest to the ORF) is
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used to drive expression of SlpA (Boot et al., 1996). It is possible however that the
upstream promoter may play a role in expression under growth conditions not yet tested.
This promoter combined with the extensive 5’ mRNA untranslated region (UTR) has
been reported to be one of the strongest expression contexts in Gram positive bacteria. At
any given time the SlpA protein can constitute as much as 10-15% of the total cellular
protein (Boot et al. 1996). The extremely high level of expression is the result of two
elements. 1) The slpA promoter is among the most efficient in lactic acid bacteria (Yeh et
al., 2008). 2) The 5’ untranslated region (UTR) folds into a highly stable loop structure
protecting the mRNA from 5’3’ degradation (Boot et al., 1996). Deletion of the 5’UTR
results in at least a 2-fold drop in expression (Boot et al., 1996, Narita et al., 2006).
The SlpA protein is composed of three components, a N-terminal leader sequence
that directs secretion, a crystallizing domain and a C-terminal anchoring domain. For the
purposes of this investigation the leader and anchor regions will be talked about in detail.
The leader sequence comprises the first 24 amino acids of the ORF and contains a leader
sequence (MKKLNR) for general secretion via the SecII secretion pathway (Figure 21b). The SecII pathway is a generalized pathway for secretion of proteins in bacteria and
has a well-conserved consensus sequence that directs cleavage of the pro-protein during
secretion. The predicted cleavage site for the slpA pro-protein is at amino acid position 24
and is consistent with the molecular weight (40.4 kD) of the mature SlpA protein (Boot et
al. 1993). The C-terminus anchoring domain is comprised of 2 tandem repeats, Sac1 and
Sac2 (Smit & Pouwels, 2002). These two sequences are primarily comprised of basic and
aromatic amino acids and share 26% identity (Figure 2-1c). Evidence suggests that the
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anchoring domain binds to peptidoglycan associated teichoic acids and that Sac1 alone is
necessary and sufficient for binding (Smit & Pouwels, 2002).
The purpose of this investigation is to address the possibility of using S-layer
derived signals to drive expression and localization of a reporter protein, green
fluorescence protein (GFP). In order to achieve this goal, a plasmid-based expression
system was utilized and the efficiency of expression and functionality of localization
elements were assessed by fluorescence microscopy and western blot analysis.
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2.2 Materials and Methods

2.2.1 Strains, plasmids and growth conditions
Several E. coli strains were utilized in this study including: TOP10 (Invitrogen),
T-1 (Zymo research), JM109, DH5α and NEB Turbo (New England Bio Labs, NEB).
Lactobacillus acidophilus NCFM was provided by the Enviromental Biotechnology
Institute, Cal Poly SLO and Lactobacillus reuteri ATCC 23272 was provided by the
Dairy Products Technology Center, Cal Poly SLO. E. coli was propagated on LuriaBertani (LB) plates and antibiotic resistant strains were selected for with erythromycin
(250 ug/mL), chloramphenicol (15 ug/mL) and ampicillin (100 ug/mL) as required.
Lactobacilli were grown in Man-Rogosa-Sharpe (MRS) media and plasmid-bearing
strains were selected for using erythromycin (5 ug/mL).
The three shuttle plasmids pGK12, pGKNucMCS and pNCKH113 were obtained
from T. Klaenhammer (North Carolina State University), The American Type Culture
Collection (ATCC- Bethesda, Maryland) and G. Tannock (University of Otago)
respectively. The plasmid pMB293 (the source of green fluorescent protein) was built
previously (M. Black) and was acquired from the laboratory collection.
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2.2.2 Molecular techniques
PCR was performed using either Taq DNA polymerase (Promega) or Phusion
DNA polymerase (Finnzymes). The primers used in this study are listed in Table 2-1. For
Taq amplifications, a 25 uL reaction volume was used with 2.5 mM MgCl2 , 0.4 uM of
each primer, 0.8 mM dNTPs, 1 unit of enzyme and 1 uL of template DNA. Typical
thermal cycling parameters for Taq DNA polymerase were as follows: Pre-denaturation
at 96°C for 2 minutes; 30 cycles of 96°C for 30 seconds, 55° for 30 seconds and 72°C for
1 minute/kb; a final elongation of 5 minutes at 72°C finished the reaction. Phusion
amplifications were performed in a 20 uL reaction volume containing 0.5 uM of each
primer, 0.8 mM dNTPs, 1 unit of enzyme and 1 uL of template DNA. Thermal cycling
parameters for Phusion DNA polymerase were according tot the manufacturer’s
instructions: Pre-denaturation at 98° for 1 minute; 30 cycles of 98°C for 30 seconds, 55°C
for 30 seconds and 72°C for 30s/kb; a final 2 minute extension at 72°C concluded the
reaction. When colony PCR was used to screen for recombinant clones, a Taq reaction
was set up as described previously except that the template consisted of raw cells from a
potential clone.
Restriction enzyme digestions were performed using approximately 1 ug of DNA
according to the reaction conditions suggested by NEB. If the digest was diagnostic, a 10
uL reaction volume was used, if the product was to used for downstream application such
as ligation, the digest was performed in 20-30 uL reaction volumes using the appropriate
10X reaction buffer (NEB). Double digestions were performed in the buffer
recommended by NEB. Sequential digestions were performed in two separate digestion
reactions, each containing the optimal buffering conditions for the enzyme to be used.
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After the first digest was performed the intermediate DNA product was gel or column
purified (Gel Spin, Zymo research) and the eluted product was digested in a second
reaction with the suggested buffering conditions for the second enzyme.
Ligations were performed in 10 uL reaction volumes. For classical cloning of
cassette DNA into plasmids, a 4:1 insert:vector molar ratio was used with approximately
250 ng of linearized plasmid DNA. For cassette construction, a 1:1 ratio between
components was used. The reactions were ligated at room temperature or 16°C for 30
minutes to 2 hours. After incubation plasmid ligations were transformed into E. coli.
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2.2.3 Transformation of plasmid DNA into E. coli
After ligation, 5 uL or 1 uL of the ligation reaction was transformed into
chemically or electrocompetent E. coli, respectively, according to manufacturers
instructions. When transforming pGK12-derived plasmids, a subinhibitory concentration
of erythromycin (100 ng/mL) was added to the recovery medium (SOC) to induce
expression of the ErmC promoter and the recovery time was extended to two hours. After
recovery and/or induction the cells were plated onto selective media.

2.2.4 Transformation of plasmid DNA into Lactobacillus
Two different transformation methods were utilized to transform Lactobacillus
acidophilus and Lactobacillus reuteri. For L. acidophilus a modified method from Kim et
al. (Kim et al., 2005) was used. An overnight culture of L. acidophilus, grown in MRS,
was used to inoculate 5 mL of MRS+1% glycine (1:50 initial inoculum), the culture was
grown until OD600=0.3 and the cells were harvested by centrifugation at 4000Xg for 10
minutes at 4°C. The cells were washed 2X with ice-cold wash buffer (5 mM NaPO4, 1
mM MgCl2, pH 7.4) and resuspended in 1/10 volume electroporation buffer (1 M
sucrose, 3 mM MgCl2, pH 7.4). After resuspension, 80 µL of competent cells were added
to an electroporation cuvette with an inner-electrode gap of 0.2 cm (Bio-Rad). Next, 5 µL
of plasmid DNA (~1 ug) was added to the cells and the mixture was incubated on ice for
10 minutes. A single pulse of 1.5 kV and 480 Ω was applied for an approximate pulse
length of 16 ms. Immediately following the pulse, the cells were recovered in 1.0 mL prewarmed MRS for 20 minutes at 37°C. If the plasmid required induction, (pGK12-derived
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plasmids) then erythromycin was added to 100 ng/mL and incubated a further 3 hours at
37°C. After induction, 250 µL of the recovered cells were inoculated into 5 mL MRS
with 5 µg/mL erythromycin and incubated either anaerobically or in candle jar overnight
for the enrichment of transformants. After enrichment, 50 µL was spread onto MRS with
5 µg/mL erythromycin plates and incubated for 48 hours in a candle jar until colonies
were visible.
For Lactobacillus reuteri a modified transformation procedure from Ahrne et al.
was utilized (Ahrne et al., 1992). MRS was inoculated with a 1:100 initial inoculum from
a fresh overnight MRS broth culture. The cells were grown to OD600=0.6 and harvested
by centrifugation as described above. The cells were washed 2X with ice-cold water and
1X with 1/10 volume of EHR (1mM HEPES, 0.5 M raffinose, pH 7.0) buffer. The cells
were then resuspended in 1/100 volume of EHR buffer and 100 µL aliquots were made in
1.5 mL microcentrifuge tubes. Approximately 5 µL (~1 µg) of plasmid DNA was added
to 100 µL aliquots and incubated on ice for 10 minutes. The remainder of the
electroporation and recovery/selection procedure was the same as for L. acidophilus.

2.2.5 Genomic DNA extraction from Lactobacillus
Lactobacillus DNA extraction was performed as previously described (Dupont et
al., 1995). Briefly, strains were grown in MRS broth (10 mL) for 48 hours and
resuspended in 1.2 mL of TES (100 mM Tris-HCl pH 7.9, 20 mM EDTA, 20 % sucrose)
with lysozyme (25 µM/ml) and mutanolysin (5 U/ml) and further incubated for 30 min at
37°C. Then, 80 µL of 10% SDS with proteinase K (400 µg/ml) was added and the
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mixture was incubated for 30 min at 60°C. DNA was extracted by the phenol:chloroform
method and ethanol precipitated. DNA was resuspended in 50 µL TE (10 mM Tris-HCl,
1 mM EDTA) to be used in PCR.

2.2.6 Construction of S-layer GFP fusion cassettes
All components necessary to build the S-layer GFP reporter cassettes were
amplified from extracted Lactobacillus acidophilus NCFM genomic DNA or plasmid
pMB293 (source of GFP) using the high fidelity enzyme, Phusion DNA polymerase
(Finnzymes). Each cassette was designated according to the first letter of the components
present in the given construct. For example, PLGAT contained the slpA promoter, leader,
anchor and terminator as well as GFP as a reporter. For simplicity only the construction
of one cassette (PLGAT) will be provided here in detail, all other cassettes were built
analogously. GFP 5’ Seq contains only the 5’ ~100 nucleotides of GFP (and the 5’ AscI
site) and was necessary to build the constructs by overlap extension PCR due to the nonhomologous clamps required for efficient restriction enzyme cleavage. After
amplification the Promoter-Leader, GFP, GFP 5’Seq and Anchor-Terminator amplicons
were digested with AscI (NEB) and gel purified (Gel Spin, Zymo Research) following
manufacturers instructions. Promoter-Leader-GFP and GFP5’Seq-Anchor-Terminator
were ligated as described above, the partial cassette was then amplified using ProL-F/
GFP-Rnew or GFP5’Seq/Aterm-R primer pairs respectively. The amplified products of
the expected sizes were gel purified and diluted 1:50. Next, 1 µL of each diluted product
was mixed together in a 20 µL Phusion PCR reaction containing the primers ProL-
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F/Aterm-R. The amplicon of the expected size was gel purified and stored at -20°C until
use.

2.2.7 Construction of the pGKMCS shuttle plasmid
pGKMCS was built according to Figure 2-2 Briefly, the multiple cloning
sequence (MCS) of pCR2.1 (Invitrogen) was amplified using TS315-F and TS315-R
primers, which bind approximately 200 nucleotides flanking the MCS using Phusion
DNA polymerase. The amplicon was gel purified and digested with NsiI. The plasmid
pGKNucMCS was digested with XhoI and end filled using T4 DNA polymerase (NEB).
The end-filling reaction contained 3 units of T4 DNA polymerase, 0.1 mM dNTPS, ~ 2
µg of freshly digested and heat inactivated plasmid and 1X NEB buffer 3 in a 25 µL
reaction volume. The reaction was incubated at 12°C for 15 minutes then heat inactivated
at 65°C for 20 minutes. The plasmid was then digested with NsiI and gel purified. A
blunt/sticky end ligation was performed to clone the insert into the linearized vector. This
ligation was performed at room temperature overnight. The ligation product was
transformed into chemically competent TOP10, induced for 2 hours and plated onto
selective media (LBE250). Successful recombinant clones were confirmed by plasmid
extraction and diagnostic digests using enzymes unique to the newly introduced MCS.
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2.2.8 Classical cloning of S-layer GFP cassettes into shuttle plasmids
When the target cloning plasmid was pNCKH113 both the plasmid and insert
were digested either simultaneously or sequentially with XmaI and PstI. When cloning
into pGKMCS the cassette was first digested with SmaI at 25°C for 1 hour, then PstI was
added and digested at 37°C for a further 1 hour. The vectors and inserts were ligated and
transformed as described above.

2.2.9 Digestion independent cloning of S-layer GFP cassettes into pGKMCS
Digestion independent cloning (DIC) was performed essentially as described in
Figure 2-3 except the cloning reaction only involved two steps instead of three (the
annealing step was omitted). The donor vector, pGK:slpA, was constructed by first
amplifying the full length slpA gene using Taq DNA polymerase from L. acidophilus
NCFM genomic DNA using ProL-F and Aterm-R primers. The slpA gene was then
cloned into pCR2.1 by the manufacturers instructions (R. Clarke). Next, the slpA gene
along with ~200 bp of flanking sequence was amplified from pCR2.1:slpA with the
TS315 F/R primer pair. The amplicon was then digested with EcoRI and ligated into the
EcoRI digested pGKMCS plasmid and transformed into chemically competent TOP10
cells. The DIC vector was amplified with Phusion DNA polymerase using TermDIC-F
and ProDIC-R primers. The cassettes were amplified using ProLDIC-F and AtermDIC-R
primers and the amplicons were column purified. The vector amplicon was then digested
with DpnI to remove residual pGK:slpA and heat inactivated for 20 minutes at 65°C.
Approximately 500 ng (2 µL) of vector amplicon was mixed with the appropriate amount
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of insert amplicon to achieve a 3:1 molar ratio of insert to vector. The DIC reaction
contained 4 µL of the supplied Phusion high fidelity (HF) buffer, 1.6 µL of 10 mM
dNTPs, 0.2 uL Phusion DNA polymerase and PCR grade water up to 20 µL.
Thermocycling parameters consisted of pre-denaturation at 98°C for 60 seconds, then 5
cycles of 98°C for 15 seconds and 72°C for 120 seconds, a single final extension of 5
minutes at 72°C was used to fill in any remaining gaps and finish the reaction. Finally, 5
uL was transformed into chemically competent NEB Turbo cells. Possible recombinant
clones were screened by colony PCR and fluorescence microscopy.
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2.2.10 Detection of GFP expression by western blot
Whole cell lysates were prepared from NEB Turbo E. coli cells harboring
pGK:PLGAT, pGK:PLGT, pGK:PGAT, pGK:PGT and pGK:slpA. First, 3 mLs of cells
were harvested after growth to OD600= 0.5, resuspended in PBS+0.1% Triton X-100 and
lysed by sonication 2X for 10s at power setting 5 (~14 RMS). Next, 22.5 µL of each
whole cell lysate was added to 7.5 µL of 4X SDS sample buffer (40% glycerol, 240 mM
Tris/HCl pH 6.8, 8% sodium dodecyl sulfate, 0.04% bromophenol blue and 5% βmercaptoethanol). The samples were then boiled at 99°C for 5 minutes and placed on ice
or stored at -20°C until analysis.
For western blot analysis, 20 µL of each sample was electrophoresed for 60-80
minutes @ 120V until the dye reached the bottom of the gel (12% polyacrilamide). The
proteins were transferred to a nitrocellulose membrane at 350 mA for 1 hour or 35 mA
overnight. Successful transfer was confirmed by ponceau staining and the molecular
weight standards were marked. The membrane was then blocked in 3% non-fat dry milk
in PBS-Tween (0.1%) pH 7.4 for 3 hours (at room temperature) to overnight (at 4°C)
with gentle rotation. Three washes with 15 mL PBS-Tween for 10 minutes each were
performed. This wash step was repeated after the primary and secondary antibody
incubations. The primary antibody was polyclonal chicken anti-GFP. The secondary
antibody was horseradish peroxidase (HRP) conjugated goat anti-chicken. Each antibody
was diluted 1:2000 in 10 mL PBS-Tween, added to the blot and incubated at room
temperature for 1 hour with shaking. Both the primary and secondary antibodies were
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kindly provided by John Goers of the Biochemistry Department Cal Poly, SLO. HRP was
detected by ECL+ (Amersham Biosciences) and visualized by chemiluminescent
detection.

2.2.11 Plasmid sequencing
Sequencing of cloned S-layer GFP inserts from the plasmids pGK:PLGAT,
pGK:PLGT, and pGK:PGT using the primers ProL-F and M13-R was performed by
Seqwright DNA Technology Services. The received sequence chromatograms were
visualized using 4Peaks software (A. Griekspoor and Tom Groothuis, mekentosj.com).
The sequence was manually edited to remove the ends with poor sequence data. For
pGK:PGT the forward and reverse sequencing reads were of sufficient length to allow for
manual contig assembly. This contig was then aligned to the expected sequence. When
contigs could not be assembled (pGK:PLGAT and pGK:PLGT) the individual
sequencing reads were aligned to the expected sequences. Any suspected mutations were
confirmed by inspecting the chromatograms.
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2.3 Results

2.3.1 Construction of GFP S-layer cassettes
Successful construction of the four GFP cassettes containing the expression
(promoter and terminator) and localization signals (leader and anchor) was initially
performed with Taq DNA polymerase. Subsequently, all cassettes were re-built with
Phusion DNA polymerase. Some non-target background amplification was seen in all
full-length amplicons necessitating gel purification of the desired products according to
size. To confirm that the junctions had been ligated correctly, all cassettes were digested
with AscI (Figure 2-4). Each cassette contained all of the expected individual
components from Table 2-3.
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2.3.2 Transformation of shuttle vectors into E. coli, L. acidophilus and L. reuteri
Repeated initial attempts to transform pGK12 and pGKNucMCS into various
strains of E. coli (TOP10, DH5α, T-1 and NEB Turbo) were unsuccessful unless a 1-2
hours induction period was included during the recovery stage (see Materials and
Methods). Transformation of pGK12 and pCKNucMCS into L. acidophilus and L.
reuteri after induction were successful resulting in antibiotic resistant colonies after 48
hours.
Transformation of pNCKH113 into E. coli TOP10 and into L. reuteri ATCC
23272 was assumed to be successful, as plasmid DNA of the appropriate size and
digestion pattern for pNCKH113 was regularly recovered from E. coli and L. reuteri.
However, repeated transformation attempts into L. acidophilus NCFM were
38

unsuccessful. To determine if the inability to recover erythromycin resistant clones was
due to incompatibility of this plasmid in L. acidophilus or if L. acidophilus was simply
not amenable to transformation, pGK12 was transformed into L. acidophilus.
Transformation of pGK12 into L. acidophilus resulted in antibiotic resistant clones after
~48 hours, suggesting a problem with replication, selection or maintenance of
pNCKH113 in L. acidophilus. In order to achieve a sufficiently broad host range, the
pGKNucMCS derived plasmid, pGKMCS was utilized for all cassette cloning. The
pGKMCS shuttle plasmid contains the multiple cloning sequence from pCR2.1 as well as
the origin and erythromycin resistance marker from pGK12 and was able to be
transformed into all organisms tested. The transformation efficiencies in L. reuteri and L.
acidophilus NCFM were very low (<102 and <10 cfu/ug respectively), in spite of
multiple attempts to optimize the electroporation parameters.

2.3.3 Cloning of S- layer GFP cassettes into pGKMCS and expression in E. coli
The insertion of S-layer GFP cassettes into pGKMCS using classical cloning
techniques was repeatedly unsuccessful. Likewise, sub-cloning of the cassettes into
pCR2.1 or pCR4 TOPO cloning vectors resulted only in the recovery of clones that did
not contain the inserts of interest. However, sub-cloning of the wild type slpA gene
(amplified from L. acidophilus genomic DNA using ProL-F and Aterm-R) into pCR2.1
and subsequent ligation into pGKMCS was successful.
To efficiently clone the GFP reporter cassettes into pGKMCS a digestion
independent cloning (DIC) technique was developed (Figure 2-3). DIC allows for
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orientation specific cloning using sequence homology between the insert and vector. For
DIC, insert and vector DNA containing homology at each end was mixed together in a
PCR extension reaction without primers and taken through 5 cycles. A relatively high
degree of success was found with this method, allowing the recovery of >100 potential
clones for each cassette. Recovered clones were screened by PCR to identify those that
were carrying the expected expression cassettes. After the clones were identified by PCR,
they were screened for GFP expression by fluorescence microscopy. Clones that were
GFP positive and PCR positive were identified for all cassettes except for PLGAT, which
only yielded PCR positive clones (Figure 2-5).
PLGT positive clones were brightly fluorescent. This fluorescence however, was
not uniform throughout the population. PGAT clones were comparatively faintly
fluorescent with only a minority of cells within the population showing any fluorescence.
PGT clones showed the most uniform fluorescence and were also bright, though slightly
duller than PLGT. No fluorescence above background could be observed with any Slayer GFP cassette bearing plasmids when transformed into L. acidophilus (Figure 2-5).
To confirm the expression of GFP and determine the size of the proteins, clones
bearing each insert were analyzed by western blotting. All clones except pGK:PLGAT
yielded distinctive GFP fusion products with bands at approximately the expected sizes
of 40.4 kD, 31.1 kD and 28.8 kD for PGAT, PLGT and PGT respectively (Figure 2-6).
Since the PLGT component contained the leader sequence, the molecular weight was
dependent on whether or not this component is cleaved in E. coli (Figure 2-1). Since the
2.3 kD difference in size cannot be resolved on this percentage acrylamide gel (12%), it
is impossible to definitively ascertain whether or not this element is properly processed
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from Figure 2-6. As a positive control for GFP, Saccharomyces cerevisiae expressing a
Pep12-GFP fusion protein (52.8 kD) was used. A negative control E. coli strain
containing a plasmid with the wild type slpA gene was also included for comparison.
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2.3.4 Sequencing of the plasmids pGKMCS:PLGAT, pGKMCS:PLGT and
pGKMCS:PGT
Three plasmids, pGKMCS:PLGAT, pGKMCS:PLGT and pGKMCS:PGT were
sequenced to elucidate reasons why PLGAT is not expressed in E. coli or Lactobacillus
and why no GFP expression can be visualized in Lactobacillus. The sequencing data is
summarized in Figure 2-4. Results for the PLGAT cassette showed a frameshift deletion
of two nucleotides at places CDS# 137, 138 (CDS = coding sequence), which resulted in
an early stop codon at CDS# 175-177. The PLGT cassette acquired a single nucleotide
insertion at CDS# 105 directly resulting in a stop codon. Due to the length of the PLGAT
and PLGT cassettes the forward and reverse sequence reads were not long enough to
build contigs resulting in gaps in the sequence alignment. The gaps for the PLGAT and
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PLGT cassettes were from CDS# 430-745 and CDS# 463-484 respectively. For the
available sequence, the PGT insert appeared to be as expected, however, poor sequence
data was obtained for the 5’ end of each insert, including the sigma factor binding sites.
The percent coverage for each cassette was calculated by number of quality base reads by
the expected size for each cassette and multiplied by 100 to express as a percentage. The
percent coverage for the three inserts was 77.77, 95.43 and 95.56 for PLGAT, PLGT and
PGT respectively.

44

45

2.4 Discussion
The construction of GFP reporter constructs to assess the localization and
expression signals of slpA expression was successful as determined by diagnostic digest
patterns. While the sequence of the complete cassette could not be assessed by restriction
pattern alone, the banding pattern suggests that each insert contains the expected
component and that the AscI restriction site at the junction of each element is conserved.
All amplifications were performed with high fidelity (manufacturer reported error rate =
4.4 x 10-7) Phusion DNA polymerase making the likelihood of mutations being generated
in these cassettes due to PCR synthesis highly unlikely.
The usefulness of the selected the E. coli-Lactobacillus shuttle vectors was
determined by the criteria that a suitable vector must be easily transformed into E. coli,
possess a sufficiently broad host-range allowing introduction into various Lactobacillus
species and contain an adequate multiple cloning site for insertion of heterologous DNA.
None of the vectors initially obtained satisfied all of the above requirements. The
pNCKH113 plasmid showed narrow host specificity, as it would not transform L.
acidophilus NCFM. It was subsequently learned that the erythromycin resistance gene
harbored by this plasmid (ermGT) is not expressed in L. acidophilus (Nicholas Heng,
Personal communication). Therefore, it is possible that by replacing this antibiotic
resistance determinate with another that is expressed in L. acidophilus (i.e. the
erythromycin or chloramphenicol resistance genes from pGK12) a suitably broad host
range plasmid could be produced. The pGK12 plasmid and its derivative pGKNucMCS,
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which has the chloramphenicol resistance gene replaced with a nuclease gene from S.
aureus as a screenable marker, could not initially be transformed into E. coli. Both
chemically competent and electrocompetent cell transformation techniques were used to
initially introduce these plasmids into a variety of E. coli strains, all without success.
Though not widely reported in published material describing the use of these plasmids, a
literature search of the origin of the erythromycin and chloramphenicol resistance genes
resulted in the realization that both antibiotic resistance markers are under control of
inducible promoters. In our hands, induction during the recovery period with
subinhibitory concentrations of erythromycin (100 ng/mL) or chloramphenicol (500
ng/mL) is an absolute requirement for the recovery of antibiotic resistant transformants.
The erythromycin resistance gene, ErmC, from pGK12 was originally encoded by
a 3728 bp plasmid, pE194, initially isolated from Staphylococcus aureus (Hourinouchi &
Weisblum, 1982). The ErmC mRNA contains an extensive untranslated region,
comprising two Shine Dalgarno sequences (SD1 and SD2), that is responsible for
regulating expression of the protein. The remainder of the mRNA contains two open
reading frames, one short reading frame constituting the leader and a long reading frame
encoding the ErmC protein. The mechanism of ErmC inducible expression has since been
extensively studied and is regulated by translational attenuation (Shivakumar et al., 1980;
Gryczan et al., 1980; Dubnau, 1985; Hue & Bechhofer, 1991; Mayford & Weisblum
1989). When erythromycin is not present, only SD1 is accessible for ribosome binding
and only the 19 amino acid leader peptide is synthesized. When erythromycin is present
in low concentration, the erythromycin bound ribosome will stall at a specific place along
the ErmC mRNA while translating the leader peptide, causing a conformational shift in
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the secondary structure of the mRNA and exposing the second Shine Dalgarno sequence,
SD2. Once this sequence is accessible, the ribosome will bind to SD2 allowing for
efficient translation of the ErmC gene product. After translation, the ErmC protein
confers resistance by methylating the 23S ribosomal subunit resulting in the inability of
erythromycin to efficiently bind the ribosome and inhibit translation.
Once it was determined that pGK12 and pGKNucMCS could be readily
transformed into all organisms tested by the inclusion of an induction step, a suitable
shuttle vector with a robust multiple cloning sequence was built by incorporating the
multiple cloning sequence from the common, commercially available cloning plasmid
pCR2.1. The resulting plasmid pGKMCS contains all of the necessary requirements for
the plasmid-based study of genetic components in Lactobacillus.
Classical cloning techniques utilizing digestion of GFP reporter cassette
amplicons and the pGKMCS vector with the appropriate restriction enzymes and
subsequent ligation with T4 DNA ligase were repeatedly unsuccessful. The sub-cloning
of these amplicons into high efficiency topoisomerase-mediated (TOPO) cloning systems
was also unsuccessful. Since the TOPO vectors utilized (pCR2.1 and pCR4) are high
copy number vectors it is possible that sub-cloning was unsuccessful due to toxicity
associated with the cassettes that was amplified by the copy number of the plasmid.
Although, pGKMCS is a much lower copy number plasmid (~60 copies per cell in E. coli
– Kok et al., 1984), it was possible that the inability to recover recombinant clones was
due to the relative inefficiency of classical cloning using T4 DNA ligase. To increase
cloning efficiency, a novel method of digestion independent cloning (DIC) was
developed.
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DIC utilizes homology at the 5’ and 3’ ends between a cloning vector and the
desired insert as the driving force for cloning. By using pGK:slpA as a template to
amplify the pGK backbone along with the promoter and terminator components, we were
able to generate a cloning vector with about 200 nucleotides of homology with the 5’ and
3’ ends of each insert. Employing this cloning technique, all cassettes could be
introduced into E. coli and variable degrees of fluorescence were observed. Perhaps most
interesting were the observations that while PLGT and PGT were very bright PGAT
fluorescence was comparatively dim and non-uniform within the population and PLGAT
showed no fluorescence. This led to the hypothesis that there is toxicity associated with
the anchor, resulting in lower expression/fluorescence from the introduced cassettes.
Indeed, it was recently reported that the C-terminal region anchor region of the slpA gene
has murein hydrolase activity, for which the E. coli peptidoglycan layer is a substrate
(Acosta et al., 2008). The authors compared the C-terminal region of the slpA gene with
two other known murein hydrlolases and found a nearly universally conserved sequence
of 21 amino acids that spans the Sac1 and Sac2 domains (Acosta et al., 2008; Figure 21c). This discovery may also explain the difference in observed fluorescence between
PLGAT and PGAT, as the peptidoglycan layer in E. coli is located in the periplasmic
space. A leader driving secretion would be necessary for the anchor containing gene
fusion product to efficiently infiltrate the periplasmic space. Accumulation of murein
hydrolase activity in the E. coli periplasm could result in the inability to grow and divide,
as well as possibly compromising the integrity of the cell. We therefore reasoned that
toxicity is associated with this anchor region, especially when combined with the leader
sequence under control of the high level constitutive expression of the slpA promoter. In
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the case of the PLGAT cassette, this anchor-mediated toxicity could result only in the
recovery of clones with mutated inserts, due to selection against intact constructs. If this
line of reasoning were accurate, the anchor-less cassettes would not have the same high
degree of toxicity and would therefore not be under the same selective pressure as those
containing an anchor. To confirm that the lack of fluorescence seen in PLGAT clones
was in fact due to mutation, three plasmids, pGK:PLGAT, pGK:PLGT and pGK:PGT,
were sequenced.
As the anchor-mediated toxicity hypothesis suggested, the plasmid containing the
PLGAT insert included a deletion of two nucletides leading to a premature stop codon
just within the coding region for GFP, thus abrogating expression.
Surprisingly, the sequence for the PLGT cassette also acquired a frameshift
mutation leading to an early stop codon before the GFP open reading frame. There are
two possible explanations for the PLGT sequence containing a frameshift mutation and
yet still producing highly fluorescent cells. First, a frameshift read-through event
occurred, allowing leaky expression of the leader-GFP fusion protein. Frameshift readthrough has been well documented in E. coli (Atkins et al. 1972). This phenomenon can
occur in E. coli when the ribosome stumbles during translation and skips back into the
proper reading frame before a stop codon is encountered. This is generally a rare event,
resulting in greatly reduced expression of the mutated gene (Atkins et al. 1972), but may
be amplified in this case due to increased stumbling by erythromycin bound ribosomes.
Second, translation could have begun at the GFP start codon in the absence of classical
translation initiation signals. The region upstream of the GFP start codon was analyzed to
determine if any sequences responsible for recruiting ribosomes were present. Although
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there was no evidence to suggest a ribosome binding site, this possibility cannot be
excluded. Finally, the limited expression of GFP by either of these scenarios may be
enhanced by the very strong slpA promoter and the mRNA stabilizing effect of the slpA
5’ UTR.
According to western blot, GFP products from pGK:PLGT and pGK:PGT migrate
at the same rate during SDS-PAGE. This suggests that the product from pGK:PLGT is
either not expressing the leader sequence (compatible with explanation two) or, that the
leader region is being efficiently processed and the 1.8 kD difference between PGT and
the secreted form of PLGT cannot be resolved.
The accumulation of mutations in these inserts may also be a result of the new
DIC application, if it has an inherently high mutation rate. This is not likely however,
since all mutations were beyond the region of homology between the vector and insert,
therefore the introduction of these mutations could not be due to mis-binding during the
annealing stages of DIC. This suggests that the mutation was incorporated either during
the elongation (gap-filling) stage of DIC or during amplification of the individual
components. Based upon the reported high fidelity of the enzyme, we expect this to be a
very rare event. It is more likely that DIC has an extremely high cloning efficiency and
the toxicity associated with expression of these cassettes by the slpA promoter allowed
for the recovery of those rare clones bearing inserts that have undergone mutation during
construction. This would also explain why traditional cloning techniques were
consistently unsuccessful. The optimal parameters for DIC have not yet been completely
defined, but we are confident DIC will allow for cloning of inserts at a high enough
efficiency to allow for direct transformation into Lactobacillus and thereby eliminate the
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requirement for E. coli as an intermediate cloning host and alleviate concerns associated
with toxicity in this organism.
This investigation yielded the successful construction of a broad host range
shuttle vector with a robust multiple cloning sequence allowing relatively easy cloning
and expression of DNA in Lactobacillus and other organisms in which the pGK12
plasmid will replicate. This work also revealed toxicity of unknown origin that resulted in
an inability to recover clones containing the intact PLGAT and PLGT inserts.
Furthermore, we developed a novel cloning technique, which may allow for direct
cloning of these cassettes into Lactobacillus and bypass the toxicity problem in E. coli.
Until it is determined whether or not DIC can be used for this application, inducible
expression systems for E. coli and Lactobacillus will be used prevent selection for
mutants during cloning and allow for analysis of the slpA localization signals in both
organisms.
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3.0

Construction of inducible plasmids systems for
Lactobacillus and E. coli to determine the localization of
prolyl peptidase activity under control of the slpA
localization signals.

3.1 Introduction
As previously described, prolyl peptidases have been suggested as a potential
treatment for Celiac disease due to the unique ability of these enzymes to hydrolyze
immunogenic peptides associated with this autoimmune disease. Peptidases from the
bacterium Myxococcus xanthus (MxPEP) as well as from the mold Aspergillus niger
(ANPEP) are known to actively degrade the proline-rich peptides (Shan et al. 2004,
Stepniak et al. 2006). While Lactobacillus containing cultures have been shown to slowly
digest immunogenic peptides (Deangelis et al. 2006; Rizzello et al. 2007), the activity of
individual peptidases expressed by members of the genus against the same peptides has
not yet been investigated. The Lactobacillus genus contains three classes of proline
specific peptidases widely reported in the literature. Prolinases (PepPN) are able to cleave
proline diaminoacid (Pro-Xaa) substrates (Varmanen et al., 1998). Prolyl oligopeptidases
of the S9 family of serine proteases (S9POP) are common in the Lactobacillus genus.
Prolyl oligopeptidases generally have a predilection for peptides shorter than 30 amino
acids and exhibit variable specificity for the cleavage site with respect to the amino acids
surrounding proline residues (Polgar, 2002). Lastly, X-prolyl-diaminopeptidases
(XPDAPs) can also be found throughout the genus. A point mutation in the coding region
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for this enzyme in L. helveticus has resulted dramatic growth inhibition in milk, which
contains a large amount of proline-rich casein proteins (Yuksel & Steele., 1996).
Futhermore, some casein-derived digestion resistant peptides are rapidly degraded by
these enzymes (Degraeve & Martial-Gros, 2003). Finally, it has been shown that the one
of two enzymes that limits the rate of degradation of the CD immunodominant epitopes
in the intestine is the human XPDAP, dipeptidyl peptidase IV (DPPIV). Since all of these
peptidases are primarily localized to the cytoplasm, a secretion signal would need to be
incorporated to allow for extracellular expression and an anchoring domain may be
desirable to tether the enzyme to the exterior cell wall.
The previous chapter showed that the expression and/or localization signals
derived from the slpA gene of Lactobacillus acidophilus NCFM are toxic in E. coli,
leading to the inability to recover clones bearing intact inserts. Inducible plasmid-based
expression systems are often used to allow expression of inserts that may be toxic to their
host. To effectively assess the efficacy of using slpA localization signals to guide surface
layer expression of prolyl peptidase activity, inducible expression systems for both E. coli
and Lactobacillus are necessary. These inducible systems would allow for the expression
of the desired insert only after induction, thus preventing selection for mutants during
cloning and allowing for the controlled assessment of slpA signals in both organisms.
In E. coli, tightly regulated expression systems have been designed based upon
the regulatory features of the lac operon . A commercially available E. coli expression
system, pET30, exploits the IPTG controlled expression of the lac operon to provide a
dually regulated mechanism with strict but easily inducible expression of heterologous
proteins. Two components are essential for the system: 1) a plasmid containing the T7
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promoter under control of the lac operator; 2) a specialized host strain (BL21DE3) that
expresses the T7 RNA polymerase under control of the lac promoter and operator. This
dual layer of regulation allows for very stringent control over the expression of the cloned
sequence of interest.
To assess the effectiveness of S-layer derived expression cassettes in
Lactobacillus species, an inducible expression system based on pGK12 was conceived.
As previously described, the pGK12 shuttle plasmid contains an inducible promoter that
controls the expression of the erythromycin resistance promoter. By replacing the ErmC
open reading frame with the slpA fusion cassettes, an erythromycin inducible shuttle
vector could be constructed.
The current investigation describes the utilization of pET30 based plasmids to
assess the viability of using slpA signals to drive prolyl peptidase localization in E. coli.
Also, described in this work is the construction of an erythromycin inducible shuttle
vector, and evaluation of this plasmid’s potential to control expression of toxic protein
products in E. coli and Lactobacillus.
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3.2 Materials and Methods

3.2.1 Strains, plasmids and growth conditions
All plasmids were built and initially propagated in NEB Turbo E. coli. Cultures
were grown in Luria Bertani broth or plates. When necessary ampicilin (100 µg/mL),
chloramphenicol (15 µg/mL) and erythromycin (250 µg/mL) were added to the media to
select for plasmid harboring strains. Shuttle plasmids were built in E. coli and then
transformed into L. acidophilus according to the procedure described in chapter 2 (pg.
27) and propagated in Man-Rogosa Sharpe (MRS) broth or agar with chloramphenicol (5
µg/mL) or erythromycin (5 µg/mL). All plasmids used in this study are listed in Table
3-1. Myxococcus xanthus and Aspergillus niger were propagated in trypticase soy agar.
All molecular techniques used in this study were the same as in chapter 2 (pg. 24)
The primers used in this study are listed in Table 3-2.
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3.2.2 Amplification and cloning of prolyl peptidases
Prolyl endopeptidases from Aspergillus niger and Myxococcus xanthus have been
described previously (Stepniak et al., 2006; Shan et al., 2004). Four peptidases from L.
reuteri (S9 prolyl oligopeptidase –S9 POP, Xaa-Pro diamino peptidase- XPDAP, and
proline iminopeptidase- LrPepPN) and L. acidophilus (proline iminopeptidaseLaPepPN) were selected for sub-cloning. Amplification of peptidases was performed
with Phusion DNA polymerase using the appropriate primer pair listed in Table 3-2 and
according to previously described thermal cycling parameters (pg 24). For all bacterial
peptidases extracted genomic DNA (ZR Fungal/Bacterial DNA Kit, Zymo Research) was
used as template for amplification. The L. reuteri peptidases were amplified from the
genome of L. reuteri 100-23C and the L. acidophilus PepPN was amplified from the
genome of L. acidophilus NCFM. The Myxococcus xanthus prolyl endopeptidase
(MxPEP) was amplified from the genome of Myxococcus xanthus ATCC 25232. For
Aspergillus niger total RNA was extracted using the RNeasy kit (Qiagen) and converted
to cDNA using the Superscript cDNA synthesis kit (Invitrogen) according to
manufacturers instructions. After cDNA synthesis ANPEP was amplified by Phusion
DNA polymerase as previously described except the cycle number was increased to 40.
All amplified peptidases were sub-cloned into the TOPO-blunt vector pCR4 (Invitrogen)
according to manufacturers instructions.
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3.2.3

Construction of the erythromycin inducible expression vector pGKΔErm
pGKΔErm was incidentally built by M. Black for a related thesis topic. Primers

with 5’ EcoRI sites were designed from pGK12 to delete the open reading frame of ErmC
but preserve the promoter and terminator sequences, as well as the remainder of the
pGK12 backbone (Ermdel-F/R). The resulting amplicon was digested with EcoRI and
ligated to re-circularize creating pGKΔErm. After transformation, this plasmid was
selected for using the remaining chloramphenical resistance marker.

3.2.4

Construction of the PLGST cassette and amplification of LGS
The Promoter-Leader-GFP-Sac1-Terminator cassette was built by gap-fill PCR.

The Promoter-Leader-GFP, and 5’ GFP seq-Sac1 and Term gene fusion products were
amplified by PCR with the uncloned PLGAT amplicon as template and the appropriate
primer pairs (ProL-F/GFP-R, 5’ GFP seq/Sac1-R and Term-F/Aterm-R, respectively)
using Phusion DNA polymerase. The Sac1-R primer contained 20 nucleotides of
homology with the 5’ end of the slpA terminator. For gap-fill PCR, 2 µL of each
amplicon was mixed together in a 20 µL Phusion reaction, the thermocycling parameters
were as follows: 98°C for 1 minute 5 cycles of 98°C for 10 seconds, 60°C for 30 seconds
and 72°C for 45s and a final elongation at 72°C for 2 minutes. Immediately following the
gap-fill reaction, 1 µL of HF buffer, 1 µL of 10 µM ProL-DIC-F, 1 µL of 10 µM AtermDIC-R and 2 µL of H2O was added and taken through PCR parameters as described
previously for Phusion. The promoter-less and terminator-less Leader-GFP-Sac1 (LGS)
gene fusion product was amplified from PLGST with LeadE1N1-F and Sac1E1-R
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primers to provide compatible restriction sites for introduction into pGKΔErm (via
EcoRI) and pET30a (via NdeI and EcoRI).

3.2.5 Construction of pGKΔErm:LGS, pGKΔErm:LXaaProS and pET30a:LXaaProS,
pET30a:LS
The LGS amplicon was digested with EcoRI and ligated into EcoRI linearized
pGKΔErm to create pGKΔErm:LGS. Colony PCR was used to identify clones that had
the introduced LGS cassette in the propero orientation to place it behind the ErmC
promoter. The pGKΔErm:LXaaProS plasmid was created by digesting pGKΔErm:LGS
with AscI to remove GFP then ligating AscI digested XaaPro from pCR4:XaaPro. After
plasmid propagation and extraction in E. coli, pGKΔErm:LGS, pGKΔErm:LXaaProS and
pGKΔErm were transformed into L. acidophilus NCFM.
Since the XaaPro sequence contained two NdeI sites, a two-step cloning strategy
was required to build pET30:LXS. The plasmid pET30:LS was constructed during the
first step. The Leader-Sac1 (LS) cassette was amplified from the Promoter-Leader-Sac1Terminator (PLST) construct which was built by gap-fill PCR similar to PLGST (J.
Labarge). 5 µL of LS was then digested with NdeI in a 20 µL reaction containing 2 µL 10
X EcoRI buffer, 1 µL of NdeI and 11 µL H2O and incubated at 37°C for 1 hour. After the
initial 1 hour incubation, 1 µL of EcoRI was added and the reaction was incubated a
further 1 hour at 37°C after which it was heat inactivated (65°C for 20 mins) and ligated
into NdeI and EcoRI digested pET30a (Novagen) to form pET30a:LS. The
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pET30a:LXaaProS plasmid was built by linearizing pET30:LS with AscI and ligating in
the gel purified AscI digested XaaPro sequence from pCR4:XaaPro.

3.2.6 Western blot analysis of inducible GFP expression from pGKΔErm:LGS
E. coli bearing pGKΔErm:LGS and pGKΔErm (negative control) were grown in
LB-Chloramphenicol (15 µg/mL) to OD600 = 0.5 then induced for two hours with 10
ng/mL erythromycin. Uninduced controls were grown without induction for two hours.
Three OD600 units (i.e. 6 mL @ OD600 = 0.5) was harvested at the 0 minute induction
timepoint and the two hour induction time point. The samples were centrifuged at
4000Xg for 10 minutes at 4°C and 1 mL of the media was removed and stored at -80°C
(Media fraction). The remaining media was discarded and the cells were washed 1X with
PBS pH 7.4, pelleted and snap frozen in liquid nitrogen and stored at -80°C. At the time
of processing, the cells were thawed and resuspended in 500 µL PBS+0.1% Triton X-100
and lysed by sonication for 2X for 10s at power setting 5 (~14 RMS). The insoluble
portion of the lysate was pelleted and the supernatant (Lysate fraction) was removed and
stored at -80°C. The remaining pellet (Pellet fraction) was also stored @ -80°C. AntiGFP western blot was performed according to the protocol on pg. 35. In each case the
volumes were normalized so as to load an equal volume relative to the original sample of
each fraction into each lane.

62

3.2.7 His-tag detection of pET30 expressed proteins
The pET30:LS and pET30:LXS plasmids, were transformed into E. coli
BL21DE3 (Novagen). Overnight cultures in LB-Kanamycin (10 µg/mL) were diluted
100-fold in the same medium and grown to OD600 = 0.5, at which point each culture was
induced for two hours with 1 mM IPTG at 37°C with shaking. The media, lysate and
pellet fractions were collected as described above. Detection of full-length protein
expression was accomplished using an HRP conjugated His Probe (Pierce), which binds
to the His-tag and can visualized using the ECL+ detection reagent (Amersham
Biosciences). The His-tag detection and visualization was carried out according to the
manufacturers instructions.

3.2.8 Growth curves analysis of pET30 plasmids
E. coli BL21DE3 cells bearing the pET30:LS and pET30:LXS plasmids were
cultured overnight in LB-Kanamycin (10 µg/mL), diluted 100-fold in the same medium
then grown to OD600 = 0.5 and induced as described above. OD600 readings were taken at
the time of induction (0 time point) and then every 15 minutes for 2 hours. Uninduced
controls were used for microscopic comparison.
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3.2.9 Prolyl peptidase activity assays
E. coli BL21DE3 harboring pET30:LXS and NEB Turbo E. coli with
pGKΔErm:LXS or pGKΔErm (negative control) were grown overnight in the appropriate
selective media. The cultures were diluted 100-fold and grown to OD600 = 0.5 and
induced for two hours with either 1mM IPTG (pET30:LXS) or 10 ng/mL erythromycin
(pGKΔErm:LXS and pGKΔErm). Whole cell lysates were prepared as described above
with the exceptions that the cells were sonicated in 500 µL of 1 mM Tris-HCl (pH 8.0)
and the insoluble material was not pelleted after lysis. Intact cell samples were harvested
by centrifugation, washed one time in 1 mM Tris-HCl pH 8.0 and resuspended in 500 µL
of 1 mM Tris-HCl pH 8.0.
Lactobacillus NCFM harboring pGKΔErm and pGKΔErm:LXS were grown to
OD600 = 0.5 and harvested after two hours of induction with 10 ng/mL erythromycin.
Whole cell lysates were prepared by resuspending in 500 µL of H2O and adding 100
units/mL of mutanolysin and 100 µg/mL of lysozyme and incubating for 30 minutes @
37°C. After protoplasting, the cells were lysed by the same sonication procedure as was
used for E. coli and lysis was confirmed by microscopy.
Peptidase assays were performed in a 96 well flat bottom optical plate (Corning)
with a 200 µL reaction volume. Each assay consisted of 180 µL of sample (whole cell
lysate, intact cells or supernatant) and 20 µL of 100mM chromogenic substrate Ala-PropNA or Gly-Pro-pNA (Bachem). Blanks consisted of 20 µL of substrate with 180 µL of
either 1 mM Tris-HCl, LB or MRS. Enzyme activity was monitored by detecting
absorbance (λ=405 nm) every 2 minutes for 20 minutes at 37°C.
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3.3 Results
3.3.1 Sub-cloning of peptidases into pCR4
Aspergillus niger prolyl endopeptidase (ANPEP), Myxococcus xanthus prolyl
endopeptidase (MxPEP), S9 prolyl oligopeptidase (S9 POP), X-prolyl diamino peptidase
(Xaa-Pro), L. reuteri PepPN (LrPepPN), and L. acidophilus (LaPepPN) were all
successfully amplified using the appropriate primer pair and template. Sub-cloning into
pCR4 was successful for five of the six peptidases of interest. In each case, cloning was
confirmed diagnostic digest of the plasmids with AscI (Figure 3-1). Cloning of the gel
purified MxPEP sequence was unsuccessful in three separate TOPO-Blunt ligations.
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3.3.2 Characterization of the erythromycin inducible plasmid pGKΔErm:LGS
An initial assay with 10 ng/mL erythromycin showed an increase in fluorescence
after 30 minutes of induction (Fig 3-2). Longer incubation times resulted in lower GFP
expression (data not shown). Instability of pGKΔErm:LGS made long term maintenance
of this plasmid in E. coli impossible. Preparation of plasmid DNA from successive
cultures of E. coli harboring pGKΔErm:LGS, showed a gradual shift from the intact
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plasmid to a smaller plasmid of unknown composition. This cryptic plasmid was
linearized by EcoRI without removing a band corresponding to LGS, the linearized
plasmid was smaller than the parental vector, pGKΔErm. After the selected clone was
found to be unstable, another clone that was positive by PCR was cultivated. This clone
showed no evidence of plasmid instability. However, this clone also showed no evidence
of GFP expression by either fluorescence microscopy (data not shown) or western blot
analysis (Figure 3-3) when compared to negative controls transformed with pGKΔErm.
Only the stable and non-fluorescent clone of pGKΔErm:LGS was successfully
introduced into Lactobacillus NCFM. The resulting clones were confirmed to contain the
intact plasmid by extraction and diagnostic digest with AscI. The transformed
Lactobacillus strain showed did not evidence of inducible GFP expression when
compared to strains harboring pGKΔErm (data not shown).
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3.3.3 Utilization of the pET30 expression system to determine the source of toxicity and
peptidase localization in E. coli.
Two pET30 based plasmids, pET30:LXS and pET30:LS were built in order to
determine the localization of peptidase expression in E. coli. To determine if toxicity was
associated with either insert, growth was monitored after induction with IPTG. The
pET30:LS plasmid showed essentially no growth after 15 minutes and even a slight drop
in OD600 after 1.5 hours post-induction. Upon induction, pET30:LXS exhibited only a
small degree of growth impairment when compared to the uninduced control (Figure 34).
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The two pET30 plasmids were designed to preserve the downstream His-tag as
part of the inducible open reading frame, thus allowing for determination of full length
insert expression by detection of the His-tag using an HRP conjugated His Probe. The
His-probe analysis showed full-length LXS expression (101.1 kD) localized to the
insoluble pellet fraction of the cell lysate. Expression of LS (12.7 kD) was much lower
and was also localized to the pellet fraction (Figure 3-5). No peptidase activity could be
detected in whole cell lysates prepared from the induced pET30:LXS cultures despite the
evidence of full-length expression of the insert by His-tag detection, perhaps suggesting
that the LXS protein is being expressed in inclusion bodies (data not shown).
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To determine if inclusion body formation was a possibility, cultures were
observed by microscopy. Distinctive morphological differences were observed between
induced cultures of E. coli harboring pET30:LXS and uninduced cultures. Induced
cultures showed drastically elongated cellular morphology with irregular coloration.
Uninduced cultures as well as the induced and uninduced pET30:LS control cultures
displayed the individual 1 µm by 2 µm rods characteristic of E. coli (Figure 3-6).
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3.4 Discussion
The first stage of this investigation involved the selection, amplification and subcloning of peptidases of interest into the TOPO-Blunt vector pCR4. Two peptidases
known to degrade celiac associated peptides, MxPEP and ANPEP, were chosen to act as
positive controls for future experiments. Only ANPEP was successfully cloned and this
was only after the PCR product of the expected size was gel purified away from smaller
background products. Cloning of the MxPEP peptidase into pCR4 was not successful.
The MxPEP amplification also showed a great deal of background amplification. After
gel purification the expected sized band was faint. This lack of product yield is the likely
reason for the inability to recover pCR4 clones containing the MxPEP insert.
Enzymes from each of the three classes of prolyl peptidases expressed in the
Lactobacillus genus were successfully amplified and sub-cloned into pCR4 (Figure 3-1).
These peptidases can be shuttled into an expression vector utilizing the engineered AscI
sites flanking each open reading frame. To assess enzyme activity in the context of the
slpA localization signals, inducible expression systems had to be utilized.
Expression of the ErmC protein is regulated by an inducible promoter that
requires a subinhibitory concentration of erythromycin for efficient translation of the
gene product. It was then reasoned that an adequate inducible E. coli-Lactobacillus
shuttle vector could be constructed by replacing the ErmC coding region with the LGS
cassette. Although, fluorescence assays indicated the induction of GFP expression
compared to the uninduced control, the plasmid appeared to be unstable and could not be
maintained. Evidence of a recombination event that removed the LGS cassette along with
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a portion of the pGK12 backbone was noted. Since this selection took place in uninduced
cultures, there is likely leakiness associated with this promoter. Leaky regulation would
allow for low-level expression of the toxic insert, leading to a high degree of selection for
mutants. Due to the observed instability and possible leakiness associated with the
pGKΔErm:LGS shuttle plasmid it was concluded that this vector was not a viable option
for inducible expression in E. coli or Lactobacillus. Since proper secondary structure of
the 5’ UTR and leader peptide are so critical for induction of the ErmC promoter, it is
worth investigating whether or not the addition of the first 50 or so nucleotides at the 5’
end of the ErmC coding region to the cassettes of interest would result in more tightly
regulated expression.
Due to the apparent failure in constructing an inducible pGK12-derived shuttle
vector, the decision was made to switch to the better-characterized pET30 vector to
regulate expression of the cassettes. The pET30:LS plasmid played a dual role in this
investigation: (1) As a negative control to be used in the pET30:LXS peptidase activity
assays. (2) Assessed toxicity associated with the S-layer localization components. Upon
induction with IPTG, growth of the pET30:LS culture was abruptly halted. This
observation provides undeniable evidence that the slpA leader and/or Sac1 anchor are
toxic to E. coli. Although an attempt was made to remove any possible murein hydrolase
activity from the anchor, the observed growth characteristics are consistent with the
continued expression of this enzyme. Cell division in E. coli is partially facilitated by a
careful balance between murein synthesizing and hydrolyzing enzymes in the periplasmic
space between the cell membrane and outer envelope (Hakenbeck & Messer, 1977). A
shift in this equilibrium due to the catalytic activity prescribed to the LS fusion protein
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might result in an inability of the cells to grow and divide, thus explaining the growth
cessation in Figure 3-4.
It was interesting to observe the distinctive difference in toxicity between the LS
insert and the LXS insert. Since the His-probe showed full-length expression of the LXS
cassette (Figure 3-5), two possible explanations remained for the attenuated toxicity
associated with LXS as compared to LS.
First, LXS may be aggregating to form inclusion bodies in the cytoplasm of E.
coli, thus is not able to elicit its toxic effects in the periplasmic space. This hypothesis
may be supported by observed differences in cellular morphology between induced and
uninduced LXS cultures. The induced culture showed drastically different morphology
and contained what may be inclusion bodies within the cells. Meanwhile the induced LS
cells showed no morphological differences from the uninduced control (Figure 3-6). The
His-tag probe results may also support this assertion, since the vast majority of protein
was associated with the insoluble cell lysate pellet. By definition, inclusion bodies are
comprised of insoluble protein aggregates and would therefore localize to the pellet
fraction after cell lysis and centrifugation. An alternative explanation for the presence of
the expressed protein in the insoluble fraction is that the Sac1 anchor is functioning
properly in E. coli and is anchoring to teichoic acid within peptidoglycan layer. If the
protein is being expressed as an inclusion body the enzyme may still be able to be
purified, re-solubilized and re-folded to determine enzymatic activity. Also, the
concentration of IPTG used for induction could be dropped in order to achieve a level of
induction that is not high enough to promote aggregation.
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Second, the attenuated toxicity may be a side effect of the introduction of the
XaaPro cassette. In this scenario, the Xaa-Pro domain could abolish toxicity associated
with the localization signals. The peptidase domain of the fusion protein may result in the
inability of the leader peptide to be recognized or properly processed in E. coli leading to
lack of secretion, which may ease the toxic affects of the insert. Likewise, if toxicity is
associated with the Sac1 anchor, then the peptidase fusion may result in a conformation
that abrogates any catalytic activity associated with this domain, thus leading to
attenuated toxicity when compared to LS. At this time, the influence of the Xaa-Pro
peptidase on toxicity has not been determined.
To properly assess the source of toxicity in E. coli (Leader or Sac1 or both), new
plasmids allowing for every possible permutation of these components, are being built.
These new plasmids (pET30:LX, XS, X, L, and S) may also provide insight into the
reason why there is no Xaa-Pro peptidase activity detectable in induced pET30:LXS
whole cell lysates. The lack of peptidase activity may be a result of at least two
possibilities. The peptidase domain may not be able to fold correctly when fused to the
Leader and/or Sac1 components, and /or this protein may require cellular components not
present in E. coli that are required for protein folding or enzymatic activity. Furthermore
microscopic and His probe analysis suggest the induced expression of LXS forms
inclusion bodies, which are unlikely to show activity. Construction and analysis of the
aforementioned vectors will provide understanding into what exactly is curtailing
peptidase activity in the present study and may elucidate a solution to this problem.
Further work is required to answer the essential questions raised by this
preliminary investigation: Are any of the selected Lactobacillus peptidases capable of
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hydrolyzing the immunodominant peptides associated with celiac disease? Can the slpA
secretion and anchoring signals be utilized to drive the localization of these peptidases
into the peptidoglycan layer of the chosen model or host organism? These questions will
not be answered quickly or easily, but will require a step wise progression through
organisms beginning with E. coli then proceeding to the model Lactobacillus acidophilus
and eventually culminating in the construction of a final product within the target, L.
reuteri.
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4.0

Concluding remarks and future research
The work described herein provides a solid technological foundation for the

genetic engineering of lactobacilli. Among these advancements is the construction of an
E. coli-Lactobacillus shuttle vector with a robust multiple cloning sequence as well as
general procedures describing molecular techniques optimized for these bacteria. A
notable achievement is the design of a novel method of digestion independent cloning
(DIC), which once fully developed may allow for direct cloning of cassettes into
Lactobacillus. This research also highlighted the unique difficulties inherent in nonmodel systems. Incompatibility between the Lactobacillus derived localization
components and the E. coli cloning host in this study resulted in the inability to recover
the desired shuttle plasmids and resulted in lost time and resources. To maximize the
likelihood of future success, a three stage experimental plan has been developed.
Stage 1: Characterization of all components in the E. coli model. This initial
investigation will allow for us to screen for prolyl peptidases that effectively hydrolyze
immunogenic peptides when fused to secretion and anchoring signals. During this stage
numerous pET30 vectors will be built to further characterize the source of toxicity
observed in this study as well as the ability of each peptidase to function while fused to
the localization signals. The peptidase activity screen will also be optimized during this
stage and perhaps a broader range of peptidases will be studied to maximize the prospect
of finding an enzyme that can be secreted and remain highly functional.
Stage 2: Determination of the functionality of S-layer localization components in
the intermediate host, L. acidophilus. This stage utilizes the organism from which the S78

layer components were originally isolated to determine if they are still functional when
expressed in recombinant form and fused to the peptidase. A strain that does not express
SlpA has also been obtained for this stage to nullify any concern of interference with
localization due to competition with the native protein. For this stage, a stable inducible
shuttle plasmid would be ideal. New inducible systems will be investigated (proteins
involved in stress response in Lactobacillus have been proposed) and the ErmC
promoter- based expression vector used in this work will be revisited in hopes of
tightening regulation. Also, during this stage high-level and low-level constitutive
promoters will be used to determine the level of expression the cell can tolerate. Here
functionality will be tested, it will be essential to find the right combination of expression
signals, localization signals and peptidase to allow proper expression in this host before
moving on to the target organism.
Stage 3: Assess the efficacy in the final host organism, L. reuteri. During the final
stage, proper surface level expression of peptidase activity will be appraised and
enymatic assays will be performed in vitro and in vivo to determine if the peptidase
delivery system is a viable treatment option for CD. In depth analysis of enzymatic
activity against the immunodominant peptides will be assessed during this stage. Not
only rates of hydrolysis but also careful study of the digestion products using HPLC and
LC-MS will be critical to ensure that the epitopes are being destroyed. In vitro analysis
will be complemented with animal models (mice and pigs?) and immunological
experiments (T-cell proliferation assays) to determine whether or not the delivery system
can function in vivo. During this exciting final stage, translational questions will finally
be addressed.
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By following this rough experimental design, future researchers are far more
likely to and prevent long, wasteful expenditures of time and money. In this investigation,
it is likely that the toxicity witnessed in the cloning host is a result of fundamental
differences between the cellular physiologies of these organisms that are not yet
completely understood. Indeed the exact function of the SlpA protein in Lactobacillus
acidophilus has not yet been completely defined. This lack of knowledge underscores a
fundamental limitation imposed by the nature of applied genetic research. The genomic
revolution has provided an incredible wealth of information from a vast number of
organisms with extremely diverse ancestry. While sequences are readily available and
predictions can be made as to the function of gene products, their physiological roles
often remain shrouded. The challenge of sifting through information and effectively
mining the data for products that may be of therapeutic importance is laid upon the
shoulders of researchers in the post-genomic era. The step-wise approach described
above provides a framework for investigators in this field. While the exact stages will
differ depending on the specific goal, it is important to be able to move through models to
prevent the over-pursuance of false leads and maintain a steady course to the final goal.
Our research aims to create an entirely new form of treatment, not only for celiac
disease but for other disorders in which enzyme supplementation through commensal
microorganisms might be useful. This goal represents a paradigm shift in the way
scientists view the human body. It is no longer seen as a collection of discrete parts that
make up a whole, but as a single, integrated biological system in which microorganisms
play a fundamental role. It is the challenge of future investigators to view the human
body as a complex and interconnected system that is dependent not only on its own
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defenses and repair mechanisms but also the ecological community of its surfaces for
optimal health and performance. This approach to the human body will require openmindedness, a broad background and interdisciplinary collaboration among a diverse
array of scientific fields, but may provide the greatest prospect for elucidating a
successful treatment for some of the most complicated and least manageable diseases.
The beneficial role that bacteria play in human health remains relatively undefined. One
must remember that the millions of years of human evolution did not happen in a
vacuum. Just as bacteria have adapted to us, we have adapted to their presence not only
around us but also within us.
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